JANX

MKT CAP:$1B

Janux Therapeutics Inc

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$16.03+$2.38 (+17.44%)

Jul 15, 2026

52W High $34.7452W Low $12.18

Company Details

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platform...

Leadership

David Alan Campbell Ph.D.Founder

President, Co-Founder, CEO & Director

Thomas Diraimondo Ph.D.

Chief Scientific Officer

Janeen Doyle

Chief Corporate & Business Development Officer

Matt Whitmire

Vice President of Finance

Maria Dobek

Vice President of Accounting

Charles M. Winter

Chief Technical Officer

James Pennington

General Counsel & Corporate Secretary

Mandie Forman-Sklansky

Head of Human Resources

IPO Date

Jun 11, 2021

Website

www.januxrx.com

Key Metrics TTM

Revenue

$14M

+235.1% YoY

Net Income

-$106M

EPS (Diluted)

Free Cash Flow

-$78M

Revenue / Share

$0.22

Gross Margin

-302.0%

Operating Margin

-1088.5%

Net Margin

-772.2%

FCF Margin

-571.6%

P/S

72.8x

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee